Targeting class i histone deacetylases in cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 1, 2013, Pages 29-41

  Delcuve, Geneviève P ^a   Khan, Dilshad H ^a   Davie, James R ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Class I HDAC inhibitor; Gene expression; HDAC complex; Histone deacetylase; RNA splicing

Indexed keywords

APICIDIN; BUTYRIC ACID; CUDC 907; DACINOSTAT; DEPSIPEPTIDE; DNA METHYLTRANSFERASE INHIBITOR; DNA TOPOISOMERASE INHIBITOR; ENTINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; MICRORNA; MOCETINOSTAT; PCI 34051; PROTEASOME INHIBITOR; ROMIDEPSIN; SPHINGOSINE 1 PHOSPHATE; TEFINOSTAT; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

CANCER PROGNOSIS; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COMPLEX FORMATION; CUTANEOUS T CELL LYMPHOMA; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENOME; GENOMIC INSTABILITY; HUMAN; LYMPHATIC SYSTEM TUMOR; NEUROBLASTOMA; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; RNA SPLICING; RNA STABILITY; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 84871209715     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.729042     Document Type: Review

References (129)

1. Witt O, Deubzer HE, Milde T, et al. HDAC family: what are the cancer relevant targets? Cancer Lett 2009;277:8-21
2. Wagner JM, Hackanson B, Lubbert M, et al. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 2010;1:117-36
3. Drummond DC, Noble CO, Kirpotin DB, et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005;45:495-528 (Pubitemid 40261815)
4. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004;338:17-31 (Pubitemid 38429783)
5. Allis CD, Berger SL, Cote J, et al. New nomenclature for chromatin-modifying enzymes. Cell 2007;131:633-6 (Pubitemid 350089969)
6. De Ruijter AJ, Van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-49 (Pubitemid 36399066)
7. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-32 (Pubitemid 47255924)
8. Kahali S, Sarcar B, Prabhu A, et al. Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response. FASEB J 2012;26:2437-45
9. Luo Y, Jian W, Stavreva D, et al. Trans-regulation of histone deacetylase activities through acetylation. J Biol Chem 2009;284:34901-10
10. Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 2012;4:5
11. Tsai SC, Seto E. Regulation of histone deacetylase 2 by protein kinase CK2. J Biol Chem 2002;277:31826-33 (Pubitemid 34968989)
12. Brandl A, Heinzel T, Kramer OH. Histone deacetylases: salesmen and customers in the post-translational modification market. Biol Cell 2009;101:193-205
13. Segre CV, Chiocca S. Regulating the regulators: The post-translational code of class I HDAC1 and HDAC2. J Biomed Biotechnol 2011;2011:690848
14. Sun JM, Chen HY, Moniwa M, et al. The transcriptional repressor Sp3 is associated with CK2 phosphorylated histone deacetylase 2. J Biol Chem 2002;277:35783-6
15. Sun JM, Chen HY, Davie Jr. Differential distribution of unmodified and phosphorylated histone deacetylase 2 in chromatin. J Biol Chem 2007;282:33227-36 (Pubitemid 350161740)
16. Pluemsampant S, Safronova OS, Nakahama K, et al. Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors. Int J Cancer 2008;122:333-41 (Pubitemid 350234719)
17. Barnes PJ. Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009;3:235-43
18. Rahman I, Kinnula VL, Gorbunova V, et al. SIRT1 as a therapeutic target in inflammaging of the pulmonary disease. Prev Med 2012;54(Suppl):S20-8
19. Gocke CB, Yu H. ZNF198 stabilizes the LSD1-CoREST-HDAC1 complex on chromatin through its MYM-type zinc fingers. PLoS One 2008;3:e3255
20. Silverstein RA, Ekwall K. Sin3: A flexible regulator of global gene expression and genome stability. Curr Genet 2005;47:1-17 (Pubitemid 40069110)
21. Hayakawa T, Nakayama J. Physiological roles of class I HDAC complex and histone demethylase. J Biomed Biotechnol 2011;2011:129383
22. Hurst DR. Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes. Cancer Metastasis Rev 2012. [Epub ahead print]
23. Telles E, Seto E. Modulation of cell cycle regulators by HDACs. Front Biosci (Schol Ed) 2012;4:831-9
24. Denslow SA, Wade PA. The human Mi-2/NuRD complex and gene regulation. Oncogene 2007;26:5433-8 (Pubitemid 47255925)
25. Wang Y, Zhang H, Chen YP, et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009;138:660-72
26. Liang J, Wan M, Zhang Y, et al. Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. Nat Cell Biol 2008;10:731-9 (Pubitemid 351772939)
27. Lakowski B, Roelens I, Jacob S. CoREST-like complexes regulate chromatin modification and neuronal gene expression. J Mol Neurosci 2006;29:227-39
28. Battaglia S, Maguire O, Campbell MJ. Transcription factor co-repressors in cancer biology: roles and targeting. Int J Cancer 2010;126:2511-19
29. Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 2012;31:537-51
30. Jelinic P, Pellegrino J, David G. A novel mammalian complex containing Sin3B mitigates histone acetylation and RNA polymerase II progression within transcribed loci. Mol Cell Biol 2011;31:54-62
31. Lahm A, Paolini C, Pallaoro M, et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci USA 2007;104:17335-40 (Pubitemid 350219843)
32. Watson PJ, Fairall L, Schwabe JW. Nuclear hormone receptor co-repressors structure and function. Mol Cell Endocrinol 2012;348:440-9
33. Guo C, Gow CH, Li Y, et al. Regulated clearance of histone deacetylase 3 protects independent formation of nuclear receptor corepressor complexes. J Biol Chem 2012;287:12111-20
34. Watson PJ, Fairall L, Santos GM, et al. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature 2012;481:335-40
35. Chakraborty A, Kim S, Snyder SH. Inositol pyrophosphates as mammalian cell signals. Sci Signal 2011;4:re1
36. de la Vega L, Grishina I, Moreno R, et al. A redox-regulated SUMO/ acetylation switch of HIPK2 controls the survival threshold to oxidative stress. Mol Cell 2012;46:472-83
37. Feng D, Liu T, Sun Z, et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 2011;331:1315-19
38. McQuown SC, Wood MA. HDAC3 and the molecular brake pad hypothesis. Neurobiol Learn Mem 2011;96:27-34
39. Lu Z, Cheng Z, Zhao Y, et al. Bioinformatic analysis and post-translational modification crosstalk prediction of lysine acetylation. PLoS One 2011;6:e28228
40. Blanco-Garcia N, sensio-Juan E, de la Cruz X, et al. Autoacetylation regulates P/CAF nuclear localization. J Biol Chem 2009;284:1343-52
41. Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012;149:214-31
42. Alamdari N, Aversa Z, Castillero E, et al. Acetylation and deacetylation-novel factors in muscle wasting. Metabolism 2012; Available from: http://dx.doi.org/ 10.1016/j.metabol.2012.03.019 [Epub ahead of print]
43. Smith KT, Workman JL. Histone deacetylase inhibitors: Anticancer compounds. Int J Biochem Cell Biol 2009;41:21-5
44. Hazzalin CA, Mahadevan LC. Dynamic acetylation of all lysine 4-methylated histone H3 in the mouse nucleus: Analysis at c-fos and c-jun. PLoS Biol 2005;3:e393
45. Crump NT, Hazzalin CA, Bowers EM, et al. Dynamic acetylation of all lysine-4 trimethylated histone H3 is evolutionarily conserved and mediated by p300/CBP. Proc Natl Acad Sci USA 2011;108:7814-19
46. Hait NC, Allegood J, Maceyka M, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009;325:1254-7
47. Marks PA. Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 2010;1799:717-25
48. Wanczyk M, Roszczenko K, Marcinkiewicz K, et al. HDACi-going through the mechanisms. Front Biosci 2011;16:340-59
49. Zhou HL, Hinman MN, Barron VA, et al. Hu proteins regulate alternative splicing by inducing localized histone hyperacetylation in an RNA-dependent manner. Proc Natl Acad Sci USA 2011;108:E627-35
50. Khan DH, Jahan S, Davie JR. Pre-mRNA splicing: role of epigenetics and implications in disease. Adv Biol Regul 2012;In press
51. Rappsilber J, Ryder U, Lamond AI, et al. Large-scale proteomic analysis of the human spliceosome. Genome Res 2002;12:1231-45 (Pubitemid 41264425)
52. Mooney SM, Goel A, D'Assoro AB, et al. Pleiotropic effects of p300-mediated acetylation on p68 and p72 RNA helicase. J Biol Chem 2010;285:30443-52
53. Wilson BJ, Bates GJ, Nicol SM, et al. The p68 and p72 DEAD box RNA helicases interact with HDAC1 and repress transcription in a promoter-specific manner. BMC Mol Biol 2004;5:11
54. Hnilicova J, Hozeifi S, Duskova E, et al. Histone deacetylase activity modulates alternative splicing. PLoS One 2011;6:e16727
55. Anczukow O, Rosenberg AZ, Akerman M, et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 2012;19:220-8
56. Moore MJ, Wang Q, Kennedy CJ, et al. An alternative splicing network links cell-cycle control to apoptosis. Cell 2010;142:625-36
57. Scott GK, Mattie MD, Berger CE, et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006;66:1277-81 (Pubitemid 43259904)
58. Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E, et al. MetastamiRs: non-coding MicroRNAs driving cancer invasion and metastasis. Int J Mol Sci 2012;13:1347-79
59. Izzotti A, Cartiglia C, Steele VE, et al. MicroRNAs as targets for dietary and pharmacological inhibitors of mutagenesis and carcinogenesis. Mutat Res 2012;751:287-303
60. Reczko M, Maragkakis M, Alexiou P, et al. Accurate microRNA target prediction using detailed binding site accessibility and machine learning on proteomics data. Front Genet 2012;2:103
61. Wada T, Kikuchi J, Furukawa Y. Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8. EMBO Rep 2012;13:142-9
62. Hirsch CL, Ellis DJ, Bonham K. Histone deacetylase inhibitors mediate post-transcriptional regulation of p21WAF1 through novel cis-acting elements in the 3' untranslated region. Biochem Biophys Res Commun 2010;402:687-92
63. Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009;15:3947-57
64. Munster PN, Thurn KT, Thomas S, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011;104:1828-35
65. Ververis K, Karagiannis TC. An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis. Am J Transl Res 2012;4:24-43
66. Boumber Y, Younes A, Garcia-Manero G. Mocetinostat (MGCD0103): A review of an isotype-specific histone deacetylase inhibitor. Expert Opin Investig Drugs 2011;20:823-9
67. Chang J, Varghese DS, Gillam MC, et al. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br J Cancer 2012;106:116-25
68. Knipstein J, Gore L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opin Investig Drugs 2011;20:1455-67
69. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-93 (Pubitemid 29436325)
70. Bressi JC, De JR, Wu Y, et al. Benzimidazole and imidazole inhibitors of histone deacetylases: synthesis and biological activity. Bioorg Med Chem Lett 2010;20:3138-41
71. Pan H, Cao J, Xu W. Selective histone deacetylase inhibitors. Anticancer Agents Med Chem 2012;12:247-70
72. Bressi JC, Jennings AJ, Skene R, et al. Exploration of the HDAC2 foot pocket: synthesis and SAR of substituted N-(2- aminophenyl)benzamides. Bioorg Med Chem Lett 2010;20:3142-5
73. Soragni E, Xu C, Plasterer HL, et al. Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich Ataxia. J Child Neurol 2012;27(9):1164-73
74. Jia H, Pallos J, Jacques V, et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol Dis 2012;46:351-61
75. Bantscheff M, Hopf C, Savitski MM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011;29:255-65
76. Holson EB, Schreiber SL. Chemoproteomics quantifies complexity. Nat Biotechnol 2011;29:235-6
77. Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010;6:238-43
78. Bertrand P. Inside HDAC with HDAC inhibitors. Eur J Med Chem 2010;45:2095-116
79. Sekhavat A, Sun JM, Davie Jr. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Biochem Cell Biol 2007;85:751-8 (Pubitemid 351198422)
80. Smith KT, Martin-Brown SA, Florens L, et al. Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. Chem Biol 2010;17:65-74
81. Salisbury CM, Cravatt BF. Activity-based probes for proteomic profiling of histone deacetylase complexes. Proc Natl Acad Sci USA 2007;104:1171-6 (Pubitemid 46183977)
82. Ai T, Cui H, Chen L. Multi-targeted histone deacetylase inhibitors in cancer therapy. Curr Med Chem 2012;19:475-87
83. Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012;4:505-24
84. Needham LA, Davidson AH, Bawden LJ, et al. Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs. J Pharmacol Exp Ther 2011;339:132-42
85. Qian C, Lai CJ, Bao R, et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res 2012;18(15):4104-13
86. Lai CJ, Bao R, Tao X, et al. CUDC- 101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 2010;70:3647-56
87. Tavera-Mendoza LE, Quach TD, Dabbas B, et al. Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. Proc Natl Acad Sci USA 2008;105:8250-5 (Pubitemid 351904740)
88. Lamblin M, Dabbas B, Spingarn R, et al. Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids. Bioorg Med Chem 2010;18:4119-37
89. Guerrant W, Patil V, Canzoneri JC, et al. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J Med Chem 2012;55:1465-77
90. Jin KL, Pak JH, Park JY, et al. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol 2008;19:185-90
91. Fritzsche FR, Weichert W, Roske A, et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 2008;8:381
92. Weichert W, Roske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008;98:604-10 (Pubitemid 351214528)
93. Lehmann A, Denkert C, Budczies J, et al. High class I HDAC activity and expression are associated with RelA/ p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009;9:395
94. Chang HH, Chiang CP, Hung HC, et al. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 2009;45:610-14
95. Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 2010;28(Suppl 1):S3-20
96. Thaler F, Minucci S. Next generation histone deacetylase inhibitors: The answer to the search for optimized epigenetic therapies? Expert Opin Drug Discov 2011;6:393-404
97. Subramanian S, Bates SE, Wright JJ, et al. Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 2010;3:2751-67
98. Thurn KT, Thomas S, Moore A, et al. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011;7:263-83
99. Simboeck E, Sawicka A, Zupkovitz G, et al. A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors. J Biol Chem 2010;285:41062-73
100. Naqvi S, Macdonald A, McCoy CE, et al. Characterization of the cellular action of the MSK inhibitor SB-747651A. Biochem J 2012;441:347-57
101. Oehme I, Deubzer HE, Lodrini M, et al. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin Investig Drugs 2009;18:1605-17
102. Lee H, Rezai-Zadeh N, Seto E. Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol 2004;24:765-73 (Pubitemid 38057927)
103. Dowling DP, Gattis SG, Fierke CA, et al. Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function. Biochemistry 2010;49:5048-56
104. Nakagawa M, Oda Y, Eguchi T, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007;18:769-74
105. Vannini A, Volpari C, Filocamo G, et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004;101:15064-9 (Pubitemid 39391719)
106. Lee H, Sengupta N, Villagra A, et al. Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation. Mol Cell Biol 2006;26:5259-69 (Pubitemid 44036197)
107. Park SY, Jun JA, Jeong KJ, et al. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 2011;25:1677-81
108. Balasubramanian S, Ramos J, Luo W, et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008;22:1026-34 (Pubitemid 351689885)
109. Oehme I, Deubzer HE, Wegener D, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009;15:91-9
110. Haberland M, Mokalled MH, Montgomery RL, et al. Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev 2009;23:1625-30
111. Somoza JR, Skene RJ, Katz BA, et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004;12:1325-34 (Pubitemid 38900774)
112. KrennHrubec K, Marshall BL, Hedglin M, et al. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 2007;17:2874-8 (Pubitemid 46636249)
113. Estiu G, West N, Mazitschek R, et al. On the inhibition of histone deacetylase 8. Bioorg Med Chem 2010;18:4103-10
114. Tang W, Luo T, Greenberg EF, et al. Discovery of histone deacetylase 8 selective inhibitors. Bioorg Med Chem Lett 2011;21:2601-5
115. Brunsteiner M, Petukhov PA. Insights from comprehensive multiple receptor docking to HDAC8. J Mol Model 2012;18(8):3927-39
116. van der Vlag J, den Blaauwen JL, Sewalt RG, et al. Transcriptional repression mediated by polycomb group proteins and other chromatin-associated repressors is selectively blocked by insulators. J Biol Chem 2000;275:697-704 (Pubitemid 30039036)
117. Bhaskara S, Hiebert SW. Role for histone deacetylase 3 in maintenance of genome stability. Cell Cycle 2011;10:727-8
118. Lagger G, O'Carroll D, Rembold M, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002;21:2672-81 (Pubitemid 34619383)
119. Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007;21:1790-802 (Pubitemid 47076478)
120. Trivedi CM, Luo Y, Yin Z, et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007;13:324-31 (Pubitemid 46376684)
121. Zimmermann S, Kiefer F, Prudenziati M, et al. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res 2007;67:9047-54 (Pubitemid 47535889)
122. Jurkin J, Zupkovitz G, Lagger S, et al. Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle 2011;10:406-12
123. Bhaskara S, Chyla BJ, Amann JM, et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 2008;30:61-72 (Pubitemid 351470157)
124. Montgomery RL, Potthoff MJ, Haberland M, et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 2008;118:3588-97
125. Fischer JJ, Michaelis S, Schrey AK, et al. SAHA Capture Compound-a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders. Proteomics 2011;11:4096-104
126. Zhang X, Ozawa Y, Lee H, et al. Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev 2005;19:827-39
127. Siddiqui-Jain A, Drygin D, Streiner N, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010;70:10288-98
128. Peng L, Ling H, Yuan Z, et al. SIRT1 negatively regulates the activities, functions, and protein levels of hMOF and TIP60. Mol Cell Biol 2012;32:2823-36
129. Beumer JH, Tawbi H. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol 2010;5:196-208